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ABSTRACT 
Given that the adult human heart has an extremely limited regenerative capacity, diseases 
characterized by contractile cell loss, as myocardial infarction and cardiomyopathies, lead 
to ventricular remodeling and heart failure. Hence, diverse strategies to promote 
myocardial regeneration have been proposed and assessed in animals and humans with 
ischemic heart disease. Of these, gene transfer and especially stem cell therapy have been 
used. So far, the overall main outcome is a gross disparity between the promising results 
obtained in mammalian models and the poor, if any, benefit observed in randomized, 
controlled clinical trials. Many reasons may account for this disappointing scenario. 
Some, including flawed trial design and methodology, differences in cell type and dosing 
as well as in route of administration, erroneous end points selection and heterogeneous 
patient populations have been extensively discussed in comprehensive reviews. Others, 
more recently addressed, signal the use of inadequate or non-precise laboratory 
techniques in cell identification and fate, this leading to precarious or misleading 
conclusions. We hereby summarize part of the work done and quote some new 
approaches, like the use of induced pluripotent stem cells and the promotion of self-
regeneration by targeting the adult cardiomyocyte cell cycle, that may cast some light in 
the otherwise shadowy field of cardiac regeneration. 
RESUMEN 
Dada la limitadísima capacidad regenerativa del corazón humano adulto, las 
enfermedades caracterizadas por pérdida de tejido contráctil, como el infarto de 
miocardio y las miocardiopatías, conducen al remodelamiento ventricular y la 
insuficiencia cardíaca. Por ello, diversas estrategias cardiorregenerativas han sido 
propuestas y evaluadas en modelos animales y pacientes con cardiopatía isquémica. De 
ellas, las más usadas han sido la transferencia génica y, especialmente, la terapia con 
células madre. Hasta aquí, el resultado global es una gran disparidad entre los 
prometedores resultados obtenidos en modelos animales y los pobres o nulos beneficios 
observados en los ensayos clínicos. Muchas razones explican este decepcionante 
escenario. Algunas, tales como imperfecciones de diseño y metodología, diferencias en 
el tipo y dosis de células así como en la vía de administración, puntos finales 
erróneamente elegidos, y heterogeneidad en las poblaciones de pacientes, han sido 
ampliamente discutidos en muy completas revisiones. Otros, más recientemente 
abordados, señalan el uso de inadecuadas o imprecisas técnicas de laboratorio para 
identificar el tipo de célula y su destino, conducentes a conclusiones precarias o 
engañosas. En este artículo resumimos parte del trabajo realizado y citamos algunos 
nuevos abordajes, tales como el uso de células pluripotentes inducidas y la auto-
regeneración por manipulación del ciclo celular del miocardiocito adulto, que podrían 
arrojar algo de luz al sombrío campo de la regeneración cardíaca. 
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Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting 
for 31% of all deaths [1]. Of note, over three quarters of CVD deaths take place in low- 
and middle-income countries [2]. Of all CVDs deaths, 46% are due to ischemic heart 
disease (IHD), and this is so in spite of all the significant advances in early reperfusion 
strategies and medical treatment occurred over the past decades. The most severe 
complication of IHD is acute myocardial infarction (AMI), after which cardiac 
remodeling takes place [3,4]. This process comprises an early phase occurring in the first 
3 days after AMI, during which the size of the infarct expands, and a late phase in which 
the remaining viable tissue undergoes hypertrophy, myocyte death, defective 
regeneration and progressive replacement of contractile myocytes by fibrotic tissue [4]. 
This progressive loss of contractile cells and their replacement by non contractile tissue 
leads to heart failure, a condition displaying about 40% one-year mortality, unless heart 
transplant is performed [5]. Diseases other than ischemic heart disease, such as dilated 
cardiomyopathy, chronic myocarditis, arterial hypertension and aortic valve stenosis, lead 
to remodeling and subsequent heart failure. According to recent estimations, heart failure 
prevalence is expected to increase, achieving approximately 46% by 2030 [6]. 
Unlike lower vertebrates (as for example the zebrafish and the salamander), the heart of 
adult mammals, including man, has very low regenerative potential, this determining that 
lost contractile tissue eventually results in heart failure. This reality has fostered, over the 
past 25 years, intense research aimed at regenerating the heart.  
Several strategies have been tested in animal models of IHD, including protein injection, 
gene transfer, stem cell therapy and implant of bioresorbable scaffolds seeded with cells 
(Figure 1). Of them, those that have awoken the largest interest and research are gene and 
stem cell therapies. In the vast majority, these studies have conveyed positive results, 
basically consisting of infarct size reduction and improvement in left ventricular function. 
However, these results have not been observed in clinical trials, in which the beneficial 
effects, if any, have been minimal and devoid of clinical relevance. 
 
Figure 1. Cardiac regeneration strategies in a heart with a myocardial infarction resulting from coronary 
artery occlusion (cross indicates site of occlusion). Angiogenic proteins (A), gene transfer in viral (B) or 
plasmidic (C) vectors, and stem cells from diverse origins (D) can be delivered using the intracoronary (left 
syringe) of direct intramyocardial (right syringe) injection routes. (E) Stem cells seeded on bioresorbable 
scaffolds (cell sheets) can be implanted on epicardial surface of the infarct. 




The present mini-review intends to summarize the principal strategies tested, point out 
some pitfalls obscuring their translational impact and refer to a couple of new approaches 
that may help to revive our hope in cardiac regeneration. 
 
Gene therapy 
Gene therapy is defined as the transfer of nucleic acids to somatic cells with a resulting 
therapeutic effect [7]. In the case of IHD, genes encoding for angiogenic growth factors 
and mitotic cytokines have been transferred using plasmidic and viral vectors in small 
and large mammalian models of chronic myocardial ischemia (CMI) and AMI. In pigs 
with Ameroid-induced CMI, we observed that the intramyocardial injection of a plasmid 
encoding human vascular endothelial growth factor-165 (VEGF165) induced, in addition 
to its classic angiogenic action, a cardiomyogenic effect consisting in a several-fold 
increase in cardiomyocyte mitotic index and cardiomyocyte hyperplasia [8,9]. These 
results, along with an attenuation of LV remodeling and improved cardiac function, were 
later confirmed in sheep with AMI at short- and long-term follow up periods [10,11]. 
VEGF165 gene therapy has been used in placebo-controlled clinical trials. The two 
largest ones were the EUROINJECT and the NORTHERN trials, including 80 and 93 
patients with angina functional class 3 to 4, respectively [12,13]. None of them resulted 
in significantly improved stress-induced myocardial perfusion compared with placebo at 
3 and 6 months follow up.  
In the placebo-controlled AGENT-2 trial, adenoviral-fibroblast growth factor-4 
(AdFGF4) or placebo administered to 52 patients with chronic angina pectoris induced a 
reduction in the LV ischemic burden [14]. On this basis, 2 new trials (AGENT 3 and 4) 
started but were discontinued when an interim analysis anticipated that the primary end 
point [a change in exercise treadmill time (ETT) duration at 12 weeks] would not be 
achieved. Later, the authors performed a pooled analysis of the 532 patients that had been 
enrolled in those 2 trials and found no differences in the same end point between groups. 
Surprisingly, when analyzing men and women separately, the differences achieved 
significance in the latter because, unlike in men, in women the placebo effect was 
negligible [15].  
Other genes (or their encoded proteins) that, on the basis of positive results in animal 
studies, have been tested in controlled clinical trials include VEGF121 [16], granulocyte 
colony-stimulating factor (G-CSF) [17], GM-CSF (granulocyte-macrophage colony 
stimulating factor [18] and FGF2 combined with VEGF165 [19]. Overall, and even in the 
few cases in which some of the end points were met, the results were disappointing in 
terms of clinical relevance. 
 
Stem Cell therapy 
Currently, the most investigated strategy for heart regeneration is the myocardial 
implantation of stem cells of diverse origins and differentiation potential. As occurs with 
gene therapy, the most habitual routes of administration are intracoronary instillation and 
direct intramyocardial injection. The cells types that after undergoing preclinical 
evaluation in animal models have been tested in randomized, placebo-controlled clinical 
trials include skeletal myoblasts (SM), bone marrow mononuclear cells (BMMC), 
mesenchymal stromal cells (MSC), and cardiac stem cells (CSC). 
When administered to patients with IHD, SM not only failed in differentiating into 
cardiomyocytes but also induced life-threatening arrhythmias [20].  
As for BMMC, more than 3000 patients have been included in over 50 clinical trials of 
IHD [21]. Of the few that were designed in a randomized, double-blind, placebo-
controlled fashion, only the REPAIR-AMI trial showed significant, though clinically 




modest, benefit [22]. In fact, a meta-analysis of 2625 patients enrolled in 50 published 
studies [23], as well as more recent reviews [24], concluded that 1) the treatment is safe, 
and 2) patients receiving BMMC displayed only moderate improvements in LV function 
parameters. Furthermore, to date, true myocardial regeneration with new cardiomyocytes 
or vessels emerging from the transplanted cells has not been shown in any clinical study. 
This is not surprising, because although the therapy approach was originally founded on 
the potential ability of bone marrow-derived stem cells to differentiate into 
cardiomyocytes, this phenomenon was later shown to be extremely rare or inexistent [25-
27]. It is now proposed (yet not studied in depth) that the benefits, if any, of these cells 
are due to paracrine effects of the multiple growth factors and cytokines that they secrete 
during the very few days that they stay viable in the injected site [28]. 
As in the case of BMMC, the controlled clinical trials carried out with mesenchymal 
stromal cells harvested from the bone marrow [29,30] demonstrated a good safety profile 
but modest or no benefit. 
In 2003 Beltrami and colleagues from the Piero Anversa’s group, using 
immunohistochemistry, reported that the adult heart contains a population of c-kit+ cells 
responsible for the normal, physiological turnover of cardiomyocytes in humans [31], and 
named them cardiac stem cells (CSC). On the basis of later studies reporting that CSC, or 
clusters of CSC termed cardiospheres, induced myocardial regeneration in animal 
models, the phase I CADUCEUS trial was conducted. In this study, intracoronary 
delivery of cardiospheres in patients with recent myocardial infarction resulted in infarct 
size reduction but no improvement in LV function [32]. Recently, studies using laboratory 
methods much more rigorous and sensitive than immunohistochemistry have severely 
and repeatedly challenged the regenerative role and even the existence of CSC in the adult 
heart [33-35]. As a consequence, several papers of the Anversa’s group have been 
retracted [36]. 
Over the past 10 years, the advent of induced pluripotent stem cells (iPSC) has casted a 
grim of light to the otherwise gloomy scenario of stem cell-induced cardiac regeneration. 
Since the pioneering work of Takahashi and colleagues [37], generating a pluripotent 
stem cell from a terminally differentiated cell has become a reality in many laboratories 
worldwide. By means of the appropriate differentiating protocol, practically any cardiac 
cell type can be obtained from iPSC. Many pitfalls, including the risk of teratoma 
formation, have to be overcome before clinical testing, but there is no doubt that this is a 
very promising field in heart regeneration. In fact, it has been recently shown that iPSC 
restore cardiac function in primates with myocardial infarction [38]. 
 
Discussion and perspectives 
The hope of repairing a failing heart, initially by transferring genes and later by 
implanting stem cells, has evolved from the enthusiasm generated by positive, promising 
results in animal models to the frustration emerging from the disappointing outcomes in 
patients. 
In a recent superb critical analysis of stem cell-mediated cardiac regeneration, Chien et 
al. have qualified this regrettable process as a scientific and clinical tragedy, and point 
out a number of reasons for it, including a tendency of the scientific community to ignore 
troubling signals, deficiencies in the peer review systems that regulates scientific 
publication, a strong tendency of the journals to privilege positive results or 
breakthroughs, lack of skepticism or self-criticism, and widespread scientific misconduct 
[39]. 
One of the problems that have not been rigorously taken into account is the fact that the 
myocardium is an electromechanical syncytium with a complex, precise physiology. 




Therefore, repopulating the heart with new cells does not suffice to mend an injured heart 
and recover its pump function. The implanted cells, even if they are shown to be 
contractile prior to implantation, should establish the correct, physiological connections 
with the resident cells. Otherwise, the pumping ability will fail to improve. So far, 
electromechanical coupling of implanted cells has not been convincingly demonstrated 
in vivo with any stem cell type, except iPSC [40]. Hence, it is not surprising that in the 
few controlled clinical trials showing positive results (note that no controlled trials using 
iPSC have been conducted) the benefit consisted in infarct size limitation but not in 
improved LV function. 
A compelling approach to overcome this limitation would be to induce the adult, resident 
cardiomyocytes to re-enter the cell cycle and divide into daughter cells through 
interventions targeting the cell cycle regulators (Figure 2). In this way the 
electromechanical coupling indispensable for an adequate functioning of the myocardial 
syncytium is more likely to be preserved, thus representing a more physiological 
approach to cardiomyogenesis [41].  
 
 
Figure 2. Schematic representation of the cardiomyocyte cell cycle. In each phase, cell cycle promoters are 
shown in green and their corresponding inhibitors in red. Transition from G1 to S allows for cardiomyocyte 
hypertrophy and the S/G2 transition results in polyploydization. Further advancement into the M phase to 
allow for mitosis and eventual cytokinesis are very infrequent, this explaining the extremely limited 
regenerative capacity of the adult myocardium. Abbreviations: Cyc: cyclin; CDK: cyclin-dependent kinase; 
Ink4 and Cip/Kip: CDKs-inhibitors families; P: pocket proteins. 
 
The classical dogma of cardiomyocytes being a totally post-mitotic cell is no longer valid. 
Adult cardiomyocytes can reenter the cell cycle and even advance into mitosis. In 
necropsies of patients dying of AMI mitotic cardiomyocytes may be found (Figure 3). 
Unfortunately, this is an infrequent event, and not at all sufficient to replace the lost 
contractile tissue. Overall, the regenerative capacity of human cardiomyocytes is very 




poor, its annual turnover rates being 1% at age 20 and 0.5% at age 50 [42]. However, 
since cardiomyocytes display cell cycle activity without cytokinesis in several processes 
such as cell growth, polyploidization and binuleation, there is a growing interest in 
disclosing cell-cycle modulators that could eventually be targeted to encourage the adult 
cardiomyocyte to divide into daughter cells. In murine cardiomyocytes there are at least 
three different levels of regulation that limit proliferation: 1) epigenetic regulation 
involving pre-transcriptional heterochromatin-mediated gene silencing of positive cell 
cycle regulators [43], 2) transcriptional activation of negative cell cycle regulators [44], 
and 3) post-transcriptional regulation through microRNAs (miRNAs) [45]. Strategies to 
intervene over these 3 levels using genes encoding proteins that stimulate cell cycle 
progression and/or microRNA that inhibit cell cycle negative regulators have been made 
in animal models, and are being intensively investigated at present [46,47]. 
While it is now too early to conclude that cardiac regeneration based on resident 
cardiomyocyte proliferation is safe, effective and feasible, it is worth continuing and 
intensifying its research, given that it is founded on a sound, physiological rationale that 
takes into account not only cardiomyogenesis but also preservation of the normal 
syncytial function. Meanwhile, basic research disclosing the multiple still unknown 
molecular mechanisms governing the cardiomyocyte cell cycle in large mammals are 
indispensable, should this compelling approach to cardiac generation be successful. 
 
 
Figure 3. Cell cycle activity in human adult cardiomyocyes as indicated by positive reaction against de 
Ki67 antigen. (A) Confocal microscopy image of polyployd cardomyocytes in a necropsy sample of a 
patient that had suffered arterial hypertension. The red staining corresponds to immunohistochemistry 
against sarcomeric α-actin. (B) Mitotic image of a cardiomyocyte in the border of a myocardial infarction 
(necropsy sample). Anti-sarcomeric α -actin immunohistochemistry and hematoxylin counterstain. 
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